This study is a prospective, cohort study to determine the quantitative threshold differences in troponin-I level between hemorrhagic and non-hemorrhagic myocardial infarction (MI).

This phase II clinical trial tests how well pembrolizumab plus enfortumab vedotin prior to and after radical nephroureterectomy works in treating patients with high-risk upper tract urothelial cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Enfortumab vedotin (EV) is a monoclonal antibody, enfortumab, linked to an anticancer drug called vedotin. It works by helping the immune system to slow or stop the growth of cancer cells. Enfortumab attaches to a protein called nectin-4 on cancer cells in a targeted way and delivers vedotin to kill them. It is a type of antibody-drug conjugate. Radical nephroureterectomy (RNU) is the surgical removal of a kidney and its ureter. Giving pembrolizumab plus enfortumab vedotin before surgery may make the tumor smaller and may reduce the amount of normal tissue that needs to be removed and giving pembrolizumab after surgery may kill any remaining cancer cells. Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632

The purpose of this study is to collect data on the performance of sensor(s) each connected to/integrated with the transmitter(s) during 7-17 days of wear (approximately 170 to 410 hours) in subjects with type 1 or type 2 diabetes, 2-80 years of age.THIS STUDY IS ENROLLING BY INVITATION ONLY 

The goal of this pilot study is to evaluate remodeling of the bone matrix and cellular composition as people age. We plan to utilize 2.5-5 ml of bone autograft and 2 ml of bone marrow aspirate from patients undergoing spinal decompression and fusion surgery to compare bone matrix and bone composition in younger (18-45) vs older patients (65-85). The material used would be obtained during the routine procedure and a small portion of the total material obtained would be used for research. This should not affect the patients’ clinical outcomes.THIS STUDY IS ENROLLING BY INVITATION ONLY - Potential patients will be identified through their treating physician at the IU Department of Neurological Surgery. Medical records/clinic schedules will also be used to screen for potential subjects. Patients who appear to be eligible will be screened for eligibility utilizing the eligibility criteria. Subjects will be initially contacted once the neurosurgeon has determined need for and the patient has agreed to undergo a spinal decompression and fusion surgery for standard indications. This may take place in the clinic or in a hospital setting or by phone. 

The purpose of this study is to establish and validate a method to quantify renal fitness in children and young adults at high risk for acute kidney injury (AKI) and chronic kidney disease (CKD) which we can use in children at high risk of CKD. We will do this by studying children and young adult patients with vesicoureteral reflux (VUR).THIS STUDY IS ENROLLING BY INVITATION ONLY - For Aims 1 and 2, individuals will be approached by a member of the study team either in person or over the phone. For Aims 3 and 4, individuals will be recruited via review of the electronic medical record. Eligible individuals will be approached by a member of the study team in outpatient nephrology clinic or over the phone.

This study will evaluate the safety and efficacy of two treatment strategies for PDR: faricimab plus PRP and Vitrectomy with endolaser with the goal to determine whether either approach decreases visit and treatment burden along with decreasing complications compared with the other treatment method while maintaining good visual acuity. The primary objectives of this study are to compare visual acuity at 3 years following vitrectomy with endolaser or faricimab+PRP and to compare number of treatments for PDR (i.e., injections, PRP, vitrectomy) following the end of randomized treatment over 3 years.THIS STUDY IS ENROLLING BY INVITATION ONLY